It Likely Will Take Longer Than 12-18 Months To Find Safe Vaccine, Whistleblower Testifies

Dr. Rick Bright testifies before the House Energy and Commerce Subcommittee on Health on May 14, 2019, in Washington, DC. - Bright filed a whistleblower complaint after he was removed in April 2020 from his post as h... Dr. Rick Bright testifies before the House Energy and Commerce Subcommittee on Health on May 14, 2019, in Washington, DC. - Bright filed a whistleblower complaint after he was removed in April 2020 from his post as head of the Biomedical Advanced Research and Development Authority (BARDA), the agency charged with developing a vaccine against coronavirus.He said he was removed for opposing the use of malaria drugs chloroquine and hydroxychloroquine for coronavirus, a treatment promoted by President Donald Trump despite little scientific evidence of success. (Photo by SHAWN THEW / POOL / AFP) (Photo by SHAWN THEW/POOL/AFP via Getty Images) MORE LESS
|
May 14, 2020 11:56 a.m.
EDITORS' NOTE: TPM is making our COVID-19 coverage free to all readers during this national health crisis. If you’d like to support TPM's reporters, editors and staff, the best way to do so is to become a member.

A vaccine expert and government whistleblower warned Thursday that the widely discussed 12-18 month timeline for a COVID-19 vaccine is “aggressive” and may not leave enough room for a full safety assessment.

“A lot of optimism is swirling around about a 12-18 month time frame, if everything goes perfectly,” testified Dr. Rick Bright, who until recently was the director of a crucial research division at the Department of Health and Human Services.

“We’ve never seen everything go perfectly,” Bright said.

Bright expressed concern that “if we rush too quickly and consider cutting out critical steps, we may not have a full assessment of the safety of that vaccine.”

A 12-18 month time frame to expect a COVID-19 vaccine Bright said, was optimistic.

“I think it’s going to take longer than that to do so,” he said, before clarifying that the 12-18 month time frame he was concerned about began when commercial and academic labs first started working on a vaccine earlier this year.

Vaccines weren’t the primary subject of Dr. Rick Bright’s testimony before the House Subcommittee on Health Thursday. The former director of BARDA, HHS’ Biomedical Advanced Research and Development Authority, was there to answer questions about his whistleblower complaint, which alleged that political pressure, bureaucratic hurdles and cronyism hampered the government’s COVID-19 response.

But Bright is a vaccine specialist and BARDA has been central to the government’s effort to support COVID-19 vaccine development.

Bright also identified potential supply chain issues that could hamper the distribution of vaccines: “Reagents and buffers and salts and various ingredients that go into a vaccine, as well as the glass vials that vaccines are put into, and needles and syringes.”

Even with a potential vaccine in hand, Bright said, there are plenty of unanswered questions that the government will need to work through — such as how to distribute and administer the vaccine widely.

“We haven’t yet gotten to those downstream strategies yet in our government, and I think those are going to become a significant issue down the road if we don’t plan for that now,” he said.

“If you can imagine the scenario this fall or winter, maybe even early next spring when a vaccine becomes available, there’s no one company that can produce enough for our country or for the world,” Bright added separately. “There’s going to be limited supplies. We need to have a strategy and plan in place now to make sure that we can not only fill that vaccine, make it, distribute it, but administer it in a fair and equitable plan.”

Key Coronavirus Crisis Links

TPM’s COVID-19 hub.
Josh Marshall’s Twitter List of Trusted Experts (Epidemiologists, Researchers, Clinicians, Journalists, Government Agencies) providing reliable real-time information on the COVID-19 Crisis.
COVID-19 Tracking Project (updated data on testing and infections in the U.S.).
Johns Hopkins Global COVID-19 Survey (most up to date numbers globally and for countries around the world).
Worldometers.info (extensive source of information and data visualizations on COVID-19 Crisis — discussion of data here).
Comments
advertisement
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Senior Editor:
Special Projects Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Publishing Associate:
Front-End Developer:
Senior Designer:
SPECIAL DEAL FOR PAST TPM MEMBERS
40% OFF AN ANNUAL PRIME MEMBERSHIP
REJOIN FOR JUST $30